74 related articles for article (PubMed ID: 14518336)
41. Effect of insulin and transferrin in the maintenance of the activated state of the T-lymphocyte induced by allo-antigen.
Helderman JH; Gruchalla R; Edwards LE
Diabetologia; 1984 Jul; 27 Suppl():99-101. PubMed ID: 6237015
[TBL] [Abstract][Full Text] [Related]
42. Heparin and platelet interactions influence alloantigen-induced proliferative responses of human T lymphocytes and immunoglobulin synthesis in vivo.
Górski A; Wasik M; Stepień-Sopniewska B; Glapiński T
Immunol Lett; 1991 May; 28(2):161-5. PubMed ID: 1832140
[TBL] [Abstract][Full Text] [Related]
43. Immunoregulatory effects of Fas-mediated signalling.
Lynch DH; Alderson MR; Ramsdell F
J Cell Biochem; 1996 Jan; 60(1):39-46. PubMed ID: 8825414
[No Abstract] [Full Text] [Related]
44. Regulation of immune reactivity and tolerance by antigen migration and localization: with particular reference to allo- and xenotransplantation.
Starzl TE; Murase N; Thomson AW; Trucco M; Rao A
Transplant Proc; 1999; 31(1-2):763-8. PubMed ID: 10083325
[No Abstract] [Full Text] [Related]
45. New approaches to inducing the death of alloreactive lymphocytes.
Krams SM
Clin Exp Immunol; 2001 Dec; 126(3):371-3. PubMed ID: 11737049
[No Abstract] [Full Text] [Related]
46. T cell death and transplantation tolerance.
Li XC; Strom TB; Turka LA; Wells AD
Immunity; 2001 Apr; 14(4):407-16. PubMed ID: 11336686
[No Abstract] [Full Text] [Related]
47. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin.
Toyoda M; Zhang XM; Petrosian A; Wachs K; Moudgil A; Jordan SC
Transpl Immunol; 1994 Dec; 2(4):337-41. PubMed ID: 7704544
[No Abstract] [Full Text] [Related]
48. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications.
Strand S; Galle PR
Mol Med Today; 1998 Feb; 4(2):63-8. PubMed ID: 9547792
[TBL] [Abstract][Full Text] [Related]
49. CD95 mediated T cell apoptosis and its relevance to immune deviation.
Varadhachary AS; Salgame P
Oncogene; 1998 Dec; 17(25):3271-6. PubMed ID: 9916989
[TBL] [Abstract][Full Text] [Related]
50. T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB.
Li-Weber M; Laur O; Dern K; Krammer PH
Eur J Immunol; 2000 Feb; 30(2):661-70. PubMed ID: 10671224
[TBL] [Abstract][Full Text] [Related]
51. Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells.
Dulat HJ; von Grumbkow C; Baars W; Schröder N; Wonigeit K; Schwinzer R
Eur J Immunol; 2001 Jul; 31(7):2217-26. PubMed ID: 11449376
[TBL] [Abstract][Full Text] [Related]
52. Alloantigen specific deletion of primary human T cells by Fas ligand (CD95L)-transduced monocyte-derived killer-dendritic cells.
Schütz C; Hoves S; Halbritter D; Zhang HG; Mountz JD; Fleck M
Immunology; 2011 May; 133(1):115-22. PubMed ID: 21342185
[TBL] [Abstract][Full Text] [Related]
53. Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity.
Strauss G; Osen W; Knape I; Jacobsen EM; Müller SM; Debatin KM
Cell Death Differ; 2007 Mar; 14(3):480-8. PubMed ID: 16902496
[TBL] [Abstract][Full Text] [Related]
54. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.
Ehl S; Hoffmann-Rohrer U; Nagata S; Hengartner H; Zinkernagel R
J Immunol; 1996 Apr; 156(7):2357-60. PubMed ID: 8786290
[TBL] [Abstract][Full Text] [Related]
55. [The CD95/CD95L system as target for modulation of allogeneic immune responses].
Schwinzer R; Dulat H; Kyas U; Wonigeit K
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):655-8. PubMed ID: 14518336
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
